6 JUNE 2025TECH OUTLOOKEditorialScientific discovery is evolving at an unprecedented pace and so is the infrastructure supporting it. As biopharmaceutical and life sciences organizations race to bring life-saving therapies to market, preclinical research and digital compliance tools have become central to that mission. Today's most successful development pipelines rely on breakthrough science, agile platforms and expert services that ensure accuracy, transparency and regulatory readiness from day one.Preclinical research services form the foundation of drug development, rigorously evaluating safety, efficacy and biology before human trials. Leading providers go beyond toxicology, offering integrated expertise in pharmacokinetics, ADME, bioanalysis and exploratory biology, reducing risk and meeting tight timelines.Behind the scenes, Veeva Solutions Providers modernize life sciences operations. Certified in Veeva's cloud platforms, they streamline document management, workflows, compliance and submissions. Amid growing regulatory demands, they ensure seamless data integration, audit trails and quality processes to keep projects compliant and on track.This edition of Pharma Tech Outlook examines how these life sciences research and technology providers are setting new benchmarks for accessibility, responsiveness and clinical excellence.Featured thought leaders include Alexis Bossie, head of media R&D at Lonza, who underscores the importance of chemically defined media systems in cell and gene therapy, which reduce variability, improve consistency and ultimately support scalable, cost-effective manufacturing. Erik Lemay, global head of external manufacturing at Servier, explains how agility, technology and end-to-end oversight are now essential for pharma companies to ensure uninterrupted patient care in an increasingly uncertain world.The magazine also spotlights leading companies like Arbor Scientia Group, a leader in scientific storytelling and medical communications. Specializing in clear, engaging content and Veeva-powered submissions, it supports diverse therapeutic areas, advancing education and accelerating time to market.We hope this edition, highlighting the Top Preclinical Research Services 2025 and Top Veeva Solutions Providers 2025, offers valuable insight into how these leaders are redefining what's possible in healthcare research and development.Let us know your thoughts!Catalysts of Scientific ProgressTECH OUTLOOKJUNE 2025, Vol 07 - Issue 08 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com Editor-in-ChiefStacey SmithEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul Barbersales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:VisualizersCelestial JordanChris LynnStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comCopyright © 2025 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Disclaimer: * Some of the Insights are based on our interviews with CIOs and CXOs
< Page 5 | Page 7 >